Benjamin C Calhoun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/720362/publications.pdf

Version: 2024-02-01

52 papers 1,011 citations

430874 18 h-index 30 g-index

52 all docs 52 docs citations

times ranked

52

1638 citing authors

#	Article	IF	CITATIONS
1	Quantitative analysis of breast cancer tissue composition and associations with tumor subtype. Human Pathology, 2022, 123, 84-92.	2.0	4
2	Risk-Associated Lesions of the Breast in Core Needle Biopsies. Surgical Pathology Clinics, 2022, 15, 147-157.	1.7	0
3	The landscape of immune microenvironments in racially-diverse breast cancer patients. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	2.5	7
4	High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision. Modern Pathology, 2022, 35, 1500-1508.	5.5	7
5	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. JNCI Cancer Spectrum, 2021, 5, pkaa072.	2.9	14
6	Protein-based immune profiles of basal-like vs. luminal breast cancers. Laboratory Investigation, 2021, 101, 785-793.	3.7	9
7	Clinical and Financial Implications of Second-Opinion Surgical Pathology Review. American Journal of Clinical Pathology, 2021, 156, 559-568.	0.7	6
8	Management of High-Risk Breast Lesions: Pointâ€"Surveillance Is a Change in Practice Preceding Evidence-Based Standardization. American Journal of Roentgenology, 2021, 216, 1432-1433.	2.2	1
9	Trichogranulomatous mastopathy: Unique pathology in a case of clinical periductal mastitis. Breast Journal, 2020, 26, 524-525.	1.0	О
10	Borderline Estrogen Receptor–Positive Breast Cancers in Black and White Women. Journal of the National Cancer Institute, 2020, 112, 728-736.	6.3	19
11	Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. Annals of Diagnostic Pathology, 2020, 48, 151576.	1.3	O
12	MRI-guided core needle biopsy of the breast: Radiology-pathology correlation and impact on clinical management. Annals of Diagnostic Pathology, 2020, 48, 151563.	1.3	10
13	Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and <i>HER2</i> Amplification. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342097638.	1.1	5
14	Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature Communications, 2019, 10, 3668.	12.8	103
15	Vascular density of histologically benign breast tissue from women with breast cancer: associations with tissue composition and tumor characteristics. Human Pathology, 2019, 91, 43-51.	2.0	3
16	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	8
17	Cystic neutrophilic granulomatous mastitis: The Cleveland Clinic experience with diagnosis and management. Breast Journal, 2019, 25, 80-85.	1.0	36
18	Joint region and nucleus segmentation for characterization of tumor infiltrating lymphocytes in breast cancer., 2019, 10956,.		26

#	Article	IF	CITATIONS
19	Analytical and clinical performance of progesterone receptor antibodies in breast cancer. Annals of Diagnostic Pathology, 2018, 35, 21-26.	1.3	5
20	Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nature Communications, 2018, 9, 578.	12.8	60
21	Benign, High-Risk, and Premalignant Lesions of the Breast. , 2018, , 116-129.e3.		5
22	Ductal Carcinoma In Situ Simultaneously Involving the Breast and Epithelial Inclusions in an Ipsilateral Axillary Lymph Node. International Journal of Surgical Pathology, 2018, 26, 564-568.	0.8	4
23	HER2 FISH concordance in breast cancer patients with both cytology and surgical pathology specimens. Journal of the American Society of Cytopathology, 2018, 7, 31-36.	0.5	6
24	Mucocele-like lesions diagnosed on breast core biopsy: Low risk of upgrade and subsequent carcinoma. Breast Journal, 2018, 24, 314-318.	1.0	18
25	Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on coreâ€needle biopsy. Cancer, 2018, 124, 459-465.	4.1	25
26	Core Needle Biopsy of the Breast. Surgical Pathology Clinics, 2018, 11, 1-16.	1.7	37
27	Breast Cancer Risk Associated With Benign Intraductal Papillomas Initially Diagnosed on Core Needle Biopsy. Clinical Breast Cancer, 2018, 18, 468-473.	2.4	9
28	Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of <i>HER2</i> gene amplification in breast cancer. Cancer, 2017, 123, 2230-2239.	4.1	28
29	Lipomatous tumors of the breast: A contemporary review. Seminars in Diagnostic Pathology, 2017, 34, 453-461.	1.5	10
30	Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Research and Treatment, 2017, 165, 499-504.	2.5	58
31	Calciphylaxis of the Postmenopausal Female Breast: An Uncommonly Encountered Mimic of Carcinoma. Case Reports in Pathology, 2017, 2017, 1-5.	0.3	5
32	Breast tissue, oral and urinary microbiomes in breast cancer. Oncotarget, 2017, 8, 88122-88138.	1.8	134
33	Endosalpingiosis of Axillary Lymph Nodes: A Rare Histopathologic Pitfall with Clinical Relevance for Breast Cancer Staging. Case Reports in Pathology, 2016, 2016, 1-5.	0.3	7
34	Breast Mass in a Woman with Recurrent Thymoma. Annals of the American Thoracic Society, 2016, 13, 2097-2098.	3.2	0
35	Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management. Annals of Diagnostic Pathology, 2016, 25, 20-25.	1.3	10
36	Radial scars diagnosed on breast core biopsy: Frequency of atypia and carcinoma on excision and implications for management. Breast, 2016, 30, 201-207.	2.2	26

#	Article	IF	CITATIONS
37	Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. Histopathology, 2016, 68, 138-151.	2.9	46
38	Triple-Negative/Basal-Like Breast Carcinomas. , 2016, , 431-443.		0
39	MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. BMC Cancer, 2016, 16, 695.	2.6	4
40	Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Research and Treatment, 2016, 158, 189-193.	2.5	21
41	Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. Modern Pathology, 2015, 28, 670-676.	5.5	47
42	Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. Seminars in Diagnostic Pathology, 2015, 32, 362-369.	1.5	47
43	Abstract P4-15-07: HER2 positive (HER2/CEP17 ratioâ%¥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy., 2015,,.		0
44	Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer: The Cleveland Clinic experience Journal of Clinical Oncology, 2015, 33, 531-531.	1.6	2
45	Breast cancer detection in axillary sentinel lymph nodes: the impact of the method of pathologic examination. Human Pathology, 2014, 45, 2497-2501.	2.0	5
46	Mitigating Overdiagnosis and Overtreatment in Breast Cancer: What Is the Role of the Pathologist?. Archives of Pathology and Laboratory Medicine, 2014, 138, 1428-1431.	2.5	6
47	Atypical apocrine adenosis diagnosed on breast core biopsy: implications for management. Human Pathology, 2014, 45, 2130-2135.	2.0	24
48	Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status Journal of Clinical Oncology, 2012, 30, 47-47.	1.6	2
49	Sampling Error in the Standard Evaluation of Endoscopic Colonic Biopsies. American Journal of Surgical Pathology, 2003, 27, 254-257.	3.7	19
50	Topical platelet growth factor therapy: of lotions and potions. Transfusion, 2001, 41, 1186-1189.	1.6	34
51	Genomic Structure of Murine Rab11 Family Members. Biochemical and Biophysical Research Communications, 2000, 269, 611-617.	2.1	27
52	A somatodendritic distribution of Rab11 in rabbit brain neurons. NeuroReport, 1996, 7, 1297-1300.	1.2	22